Carbamazepine
Treatment for Idiopathic epilepsy
Typical Dosage: 600-1200 mg daily
Effectiveness
70%
Safety Score
50%
Clinical Trials
600
Participants
80K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
600-1200 mg daily
Time to Effect
Days to weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
9(Treat 9 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$500
Monitoring:$700
Side Effect Mgmt:$400
Total Annual:$1,600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
4
Outcome-Based Costs
Cost per Responder
$4,000
Cost per Remission
$5,333
Carbamazepine Outcomes
for Idiopathic epilepsy
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+40%
Remission Rate
+30%
Common Side Effects
Dizziness
+15%
Diplopia/Blurred vision
+12%
Ataxia
+12%
Nausea/Vomiting
+8%
Rash (including serious SJS/TEN)
+7%
Hyponatremia
+3%
Leukopenia
+3%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov